Last reviewed · How we verify
Estring Vaginal Product
Estring is a vaginal ring that releases estradiol directly into vaginal tissue to treat menopausal vaginal atrophy and related symptoms.
Estring is a vaginal ring that releases estradiol directly into vaginal tissue to treat menopausal vaginal atrophy and related symptoms. Used for Atrophic vaginitis (vaginal atrophy) in postmenopausal women, Menopausal vaginal symptoms including dryness, irritation, and dyspareunia.
At a glance
| Generic name | Estring Vaginal Product |
|---|---|
| Sponsor | University of California, Irvine |
| Drug class | Estrogen replacement therapy (vaginal) |
| Target | Estrogen receptor (ER-α and ER-β) |
| Modality | Small molecule |
| Therapeutic area | Gynecology / Menopause |
| Phase | FDA-approved |
Mechanism of action
The device is a flexible plastic ring impregnated with estradiol that provides sustained, localized hormone delivery to the vaginal epithelium. This restores estrogen levels in vaginal tissue, improving lubrication, elasticity, and reducing symptoms of atrophic vaginitis without significant systemic hormone absorption. The localized delivery minimizes systemic exposure compared to oral or transdermal hormone replacement therapy.
Approved indications
- Atrophic vaginitis (vaginal atrophy) in postmenopausal women
- Menopausal vaginal symptoms including dryness, irritation, and dyspareunia
Common side effects
- Vaginal irritation or discomfort
- Headache
- Vaginal bleeding or spotting
- Breast tenderness
Key clinical trials
- Postpartum Vaginal Estrogen for Breastfeeding Patients (PHASE4)
- A Real-World Study Comparing the Efficacy of Different Treatment Regimens for Early Missed Abortion (NA)
- REVIVE: Replens Versus Intra-Vaginal Estrogen for the Treatment of Vaginal Dryness on Aromatase Inhibitor Therapy (PHASE2)
- Adherence to Vaginal Estrogen Therapy in Hypoestrogenic Women With Recurrent Urinary Tract Infections (PHASE4)
- Estrogen Administration for the Treatment of NASH in Postmenopausal Women (PHASE3)
- Comparison of Two Protocols in Frozen Embryo Transfer (NA)
- Assessing the Impact of Contraceptives on Bone Health Using 41Ca (PHASE4)
- Efficacy of Combined Pharmacotherapy Versus Solifenacin With Vaginal Estrogen Cream for Women With Detrusor Overactivity (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Estring Vaginal Product CI brief — competitive landscape report
- Estring Vaginal Product updates RSS · CI watch RSS
- University of California, Irvine portfolio CI